These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8999172)

  • 1. [The use of methotrexate in rheumatology: results and prospects].
    Nasonov EL
    Klin Med (Mosk); 1996; 74(5):10-5. PubMed ID: 8999172
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current status of methotrexate].
    Fiehn C
    Z Rheumatol; 2011 Feb; 70(2):99-100. PubMed ID: 21312022
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of methotrexate in childhood rheumatic diseases.
    Wallace CA
    Arthritis Rheum; 1998 Mar; 41(3):381-91. PubMed ID: 9506564
    [No Abstract]   [Full Text] [Related]  

  • 4. Toward a better understanding of methotrexate.
    Kremer JM
    Arthritis Rheum; 2004 May; 50(5):1370-82. PubMed ID: 15146406
    [No Abstract]   [Full Text] [Related]  

  • 5. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists.
    Gossec L; Bijlsma JW; Bombardier C; Canhão H; Devlin J; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Ostergaard M; Pereira IA; Ramos-Remus C; Zochling J; Dougados M
    Ann Rheum Dis; 2011 Feb; 70(2):388-9. PubMed ID: 20472594
    [No Abstract]   [Full Text] [Related]  

  • 6. [Chinese expert-based consensus for methotrexate in rheumatic diseases].
    Chinese Association of Rheumatology and Immunology Physicians
    Zhonghua Nei Ke Za Zhi; 2018 Oct; 57(10):719-722. PubMed ID: 30293331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon.
    Nissen MJ; Fontanges E; Allam Y; Zoulim F; Trépo C; Miossec P
    Rheumatology (Oxford); 2005 Aug; 44(8):1016-20. PubMed ID: 15855185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate--the anchor drug--an introduction.
    Pincus T; Cronstein B; Braun J
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S1-2. PubMed ID: 21044424
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenetics in the rheumatic diseases, from prêt-à-porter to haute couture.
    Cronstein BN
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):2-3. PubMed ID: 16932642
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antimalarial preparations in rheumatology: new prospects].
    Nasonov EL
    Ter Arkh; 1996; 68(1):67-71. PubMed ID: 8644039
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evidence based medicine in rheumatology].
    Gause A; Raspe HH
    Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877
    [No Abstract]   [Full Text] [Related]  

  • 12. Why is methotrexate the first selection in disease-modifying antirheumatic drug therapy? Comment on the article by Wolfe et al.
    Caballero-Uribe CV
    Arthritis Care Res; 1999 Apr; 12(2):152. PubMed ID: 10513503
    [No Abstract]   [Full Text] [Related]  

  • 13. Methotrexate induced lymphoma?
    Bleyer WA
    J Rheumatol; 1998 Mar; 25(3):404-7. PubMed ID: 9517755
    [No Abstract]   [Full Text] [Related]  

  • 14. Methotrexate for maintenance of remission in IgG4-related disease.
    Della-Torre E; Campochiaro C; Bozzolo EP; Dagna L; Scotti R; Nicoletti R; Stone JH; Sabbadini MG
    Rheumatology (Oxford); 2015 Oct; 54(10):1934-6. PubMed ID: 26139657
    [No Abstract]   [Full Text] [Related]  

  • 15. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action of methotrexate.
    Chan ES; Cronstein BN
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S5-8. PubMed ID: 24219035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate: the agent of choice for chronic inflammatory disorders. A perspective ten years later.
    Gutiérrez-Ureña S; Espinoza LR
    Clin Exp Rheumatol; 1995; 13(3):281-4. PubMed ID: 7554552
    [No Abstract]   [Full Text] [Related]  

  • 18. Do rheumatology cost-effectiveness analyses make sense?
    Wolfe F; Michaud K; Pincus T
    Rheumatology (Oxford); 2004 Jan; 43(1):4-6. PubMed ID: 14523227
    [No Abstract]   [Full Text] [Related]  

  • 19. Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy.
    Ekochin LH; Manadan AM; Aggarwal R; Sequeira W; Block JA
    J Rheumatol; 2009 Sep; 36(9):2127. PubMed ID: 19738229
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of biologics in rheumatology: improving the evidence base.
    Silman AJ; Ades AE
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv1-2. PubMed ID: 21859699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.